-

Boomerang Medical Awarded "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease" by the Crohn’s & Colitis Foundation

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation. This award, given for the first time to a medical device company, acknowledges Boomerang Medical's alignment with the Foundation’s mission to improve the lives of those affected by inflammatory bowel disease.

The Crohn’s & Colitis Foundation is a non-profit, volunteer-fueled organization dedicated to finding cures for Crohn's disease and ulcerative colitis, and to improving the quality of life of children and adults affected by these diseases, which are collectively referred to as inflammatory bowel disease (IBD). The award was presented at the Foundation's annual President’s Corporate Circle reception, held during the annual Crohn’s & Colitis Congress® on January 26, 2024. This event gathered healthcare professionals and industry leaders, providing a platform to acknowledge significant contributions in the field.

Heather Simonsen, CEO of Boomerang Medical, commented on the significance of this recognition: “We are deeply honored to be acknowledged by the Crohn’s & Colitis Foundation with this award. It reflects our shared commitment to making a tangible difference in the lives of those affected by IBD.”

Boomerang Medical's collaboration with the Crohn's & Colitis Foundation has been essential in incorporating the patient perspective into the company’s IBD research. This collaboration has led to the creation of patient advisory panels, a critical initiative that places the patient voice at the forefront of Boomerang Medical's clinical study designs. These efforts ensure that the company's research is informed by those most affected by IBD and align with the healthcare industry's broader movement recognizing the value of patient input in shaping effective and relevant clinical trials.

About the Crohn’s & Colitis Foundation:

The mission of the Crohn's & Colitis Foundation is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. The Foundation sponsors basic and clinical research of the highest quality. We also offer a wide range of educational programs for patients and healthcare professionals, while providing supportive services to help people cope with these chronic intestinal diseases. These programs are supported solely through our donors, grants, fundraising efforts, and sponsors. For more information, visit www.crohnscolitisfoundation.org.

About Boomerang Medical, Inc.

Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA for the treatment of Crohn's disease and ulcerative colitis. Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry. Current investors in the company include Arboretum Ventures and Hatteras Venture Partners. For more information, visit www.boomerangmedical.com.

Contacts

Boomerang Medical, Inc.

Details
Headquarters: Mountain View, California
CEO: Heather Simonsen
Employees: 10
Organization: PRI

Release Versions

Contacts

Social Media Profiles
More News From Boomerang Medical, Inc.

Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowel Disease

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical raises $20M Series B for pivotal neuromodulation trial in IBD. Co-led by Arboretum Ventures & Hatteras Venture Partners....

Boomerang Medical's IBD Neuromodulation Study Successfully Completes Enrollment Milestone

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical, Inc., a women-led bioelectronic medicine company focused on autoimmune diseases, proudly announced the completion of Stage 2 of its FDA-approved pilot study. This milestone marks a significant advance in the company’s research as it progresses towards its pivotal study. The BOOM-IBD Clinical Trial, the first prospective, multicenter study of its kind in the United States to explore the use of a bioelectronic technology designated as a B...

Boomerang Medical Announces First Patients Enrolled in Multi-Center Clinical Trial Evaluating Breakthrough Bioelectronic Device for Inflammatory Bowel Disease

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical, a women-led bioelectronic medicine company, has announced the enrollment of the first patients in its U.S. clinical trial evaluating the use of nerve stimulation as a potential treatment for Crohn’s disease and ulcerative colitis, the two most common forms of Inflammatory Bowel Disease (IBD). This study marks a significant milestone for the company, which was granted Breakthrough Device Designation from the U.S. Food and Drug Administra...
Back to Newsroom